

Supplementary

Table S1 Univariate and multivariate Cox proportional hazard modeling analysis for 1-year all-cause mortality (continuous TG/HDL-c)

| Variables | Univariate analysis | | Multivariate analysis | |
|----------------------|---------------------|---------|-----------------------|---------|
| | HR (95% CI) | P value | HR (95% CI) | P value |
| Age | 1.03 (1.01, 1.05) | 0.009 | 1.02 (0.99, 1.05) | 0.188 |
| Male | 3.46 (1.07, 11.16) | 0.038 | 3.34 (0.98, 11.33) | 0.053 |
| BMI | 0.94 (0.84, 1.05) | 0.265 | – | – |
| Smoking | 0.98 (0.55, 1.76) | 0.95 | – | – |
| SBP at admission | 1.01 (0.99, 1.02) | 0.250 | – | – |
| DBP at admission | 0.99 (0.97, 1.02) | 0.688 | – | – |
| Hypertension | 1.32 (0.64, 2.73) | 0.456 | – | – |
| CAD | 1.69 (0.67, 4.27) | 0.270 | – | – |
| Diabetes mellitus | 2.72 (1.35, 5.49) | 0.005 | 1.31 (0.51, 3.36) | 0.571 |
| Stroke | 3.48 (1.62, 7.47) | 0.001 | 2.64 (1.09, 6.41) | 0.031 |
| COPD | 0.79 (0.31, 2.01) | 0.624 | – | – |
| CKD | 2.67 (1.19, 5.97) | 0.017 | 2.71 (1.08, 6.82) | 0.034 |
| Timing of operation | | | | |
| Acute | Reference | – | – | – |
| Sub-acute | 0.97 (0.47, 2.03) | 0.939 | – | – |
| Chronic | 1.00 (0.37, 2.66) | 0.996 | – | – |
| Pericardial effusion | 3.3 (1.59, 6.85) | 0.001 | 0.69 (1.55, 8.80) | 0.003 |
| Pleural effusion | 1.12 (0.61, 2.05) | 0.724 | – | – |
| Glucose | 1.01 (1.00, 1.01) | 0.003 | 1.01 (1.00, 1.01) | 0.115 |
| Uric acid | 1.00 (1.00, 1.00) | 0.928 | – | – |
| TG/HDL-c | 1.07 (1.01, 1.13) | 0.030 | 1.07 (1.00, 1.15) | 0.041 |

TG/HDL-c, triglyceride to high-density lipoprotein cholesterol; HR, hazard ratio; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease.

Table S2 Univariate and multivariate Cox proportional hazard modeling analysis for 1-year all-cause mortality (TG/HDL-c ratio group)

| Variables | Univariate analysis | | Multivariate analysis | |
|-----------------------|---------------------|---------|-----------------------|---------|
| | HR (95% CI) | P value | HR (95% CI) | P value |
| Age | 1.03 (1.01, 1.05) | 0.009 | 1.03 (1.01, 1.06) | 0.007 |
| Male | 3.46 (1.07, 11.16) | 0.038 | 5.27 (1.59, 17.44) | 0.006 |
| BMI | 0.94 (0.84, 1.05) | 0.265 | – | – |
| Smoking | 0.98 (0.55, 1.76) | 0.95 | – | – |
| SBP at admission | 1.01 (0.99, 1.02) | 0.250 | – | – |
| DBP at admission | 0.99 (0.97, 1.02) | 0.688 | – | – |
| Hypertension | 1.32 (0.64, 2.73) | 0.456 | – | – |
| CAD | 1.69 (0.67, 4.27) | 0.270 | – | – |
| Diabetes mellitus | 2.72 (1.35, 5.49) | 0.005 | 1.15 (0.51, 2.58) | 0.7315 |
| Stroke | 3.48 (1.62, 7.47) | 0.001 | 3.06 (1.37, 6.86) | 0.006 |
| COPD | 0.79 (0.31, 2.01) | 0.624 | – | – |
| CKD | 2.67 (1.19, 5.97) | 0.017 | 3.08 (1.32, 7.17) | 0.009 |
| Timing of operation | | | | |
| Acute | Reference | – | – | – |
| Sub-acute | 0.97 (0.47, 2.03) | 0.939 | – | – |
| Chronic | 1.00 (0.37, 2.66) | 0.996 | – | – |
| Pericardial effusion | 3.3 (1.59, 6.85) | 0.001 | 3.01 (1.42, 6.36) | 0.004 |
| Pleural effusion | 1.12 (0.61, 2.05) | 0.724 | – | – |
| Glucose | 1.01 (1.00, 1.01) | 0.003 | 1.03 (1.00, 1.01) | 0.007 |
| Uric acid | 1.00 (1.00, 1.00) | 0.928 | – | – |
| TG/HDL-c ratio groups | | | | |
| Quintile 4 | Reference | – | Reference | – |
| Quintile 1 | 3.42 (1.12, 10.50) | 0.031 | 4.67 (1.46, 14.94) | 0.001 |
| Quintile 2 | 1.47 (0.41, 5.21) | 0.551 | 1.88 (0.52, 6.82) | 0.337 |
| Quintile 3 | 1.94 (0.58, 6.44) | 0.280 | 2.21 (0.65, 7.57) | 0.206 |
| Quintile 5 | 3.55 (1.18, 10.69) | 0.024 | 4.84 (1.55, 15.13) | 0.007 |

Quintile 1: TG/HDL-c ratio <1.44. Quintile 2: 1.44≤ TG/HDL-c ratio <2.09. Quintile 3: 2.09≤ TG/HDL-c ratio <2.97. Quintile 4: 2.97≤ TG/HDL-c ratio <4.11. Quintile 5: TG/HDL-c ratio ≥4.11. TG/HDL-c, triglyceride to high-density lipoprotein cholesterol; HR, hazard ratio; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease.

Table S3 Univariate and multivariate Cox proportional hazard modeling analysis for 1-year MACCEs (continuous TyG index)

| Variables | Univariate analysis | | Multivariate analysis | |
|----------------------|---------------------|---------|-----------------------|---------|
| | HR (95% CI) | P value | HR (95% CI) | P value |
| Age | 1.03 (1.00, 1.05) | 0.009 | 1.03 (1.00, 1.06) | 0.012 |
| Male | 3.46 (1.07, 11.16) | 0.038 | — | — |
| BMI | 0.94 (0.84, 1.05) | 0.265 | — | — |
| Smoking | 0.98 (0.55, 1.76) | 0.950 | — | — |
| SBP at admission | 1.01 (0.99, 1.01) | 0.892 | — | — |
| DBP at admission | 0.99 (0.97, 1.01) | 0.29 | — | — |
| Hypertension | 1.32 (0.56, 1.47) | 0.698 | — | — |
| CAD | 1.69 (0.44, 2.32) | 0.98 | — | — |
| Diabetes | 2.72 (0.76, 2.68) | 0.272 | — | — |
| Stroke | 3.48 (1.41, 4.78) | 0.002 | 2.60 (1.19, 5.68) | 0.016 |
| COPD | 0.79 (0.38, 1.50) | 0.418 | — | — |
| CKD | 2.67 (0.99, 3.69) | 0.054 | 2.46 (1.08, 5.61) | 0.033 |
| Timing of operation | | | | |
| Acute | Reference | — | — | — |
| Sub-acute | 0.97 (0.63, 1.75) | 0.863 | — | — |
| Chronic | 1.00 (0.77, 2.70) | 0.255 | — | — |
| Pericardial effusion | 3.30 (1.28, 4.17) | 0.005 | 3.43 (1.62, 7.25) | 0.001 |
| Pleural effusion | 1.12 (0.63, 1.54) | 0.948 | — | — |
| WBC | 1.05 (0.96, 1.08) | 0.565 | — | — |
| Creatinine | 1.00 (1.00, 1.00) | 0.100 | — | — |
| Platelet | 0.99 (1.00, 1.00) | 0.435 | — | — |
| Uric acid | 1.00 (1.00, 1.00) | 0.910 | — | — |
| TyG | 1.32 (1.18, 2.22) | 0.003 | 1.04 (0.58, 1.85) | 0.897 |

MACCEs, major adverse cardiovascular and cerebrovascular events; TyG, triglyceride-glucose; HR, hazard ratio; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; WBC, white blood cell.

Table S4 Univariate and multivariate Cox proportional hazard modeling analysis for 1-year MACCEs

| Variables | Univariate analysis | |
|-----------------------|---------------------|---------|
| | HR (95% CI) | P value |
| Age | 1.03 (1.00, 1.07) | 0.0644 |
| Male | 2.19 (0.51, 9.44) | 0.2932 |
| BMI | 0.99 (0.86, 1.15) | 0.9314 |
| Smoking | 0.98 (0.41, 2.37) | 0.968 |
| SBP at admission | 0.99 (0.97, 1.02) | 0.615 |
| DBP at admission | 0.98 (0.94, 1.02) | 0.4136 |
| Hypertension | 1.26 (0.42, 3.77) | 0.6806 |
| CAD | 4.82 (1.75, 13.27) | 0.0023 |
| Diabetes mellitus | 4.30 (1.65, 11.20) | 0.0028 |
| Stroke | 7.07 (2.71, 18.42) | <0.0001 |
| COPD | 0 (0.00, inf) | 0.9972 |
| CKD | 3.70 (1.24, 11.07) | 0.0193 |
| Timing of operation | | |
| Acute | Reference | |
| Sub-acute | 1.60 (0.62, 4.15) | 0.3324 |
| Chronic | 1.46 (0.39, 5.38) | 0.5723 |
| Pericardial effusion | 3.37 (1.13, 10.08) | 0.0299 |
| Pleural effusion | 1.12 (0.45, 2.81) | 0.8059 |
| Uric acid | 1.00 (1.00, 1.00) | 0.9566 |
| Continuous TG/HDL-c | 1.05 (0.95, 1.17) | 0.3408 |
| Continuous TyG index | 1.37 (0.69, 2.72) | 0.3654 |
| TG/HDL-c ratio groups | | |
| Quintile 4 | 4.67 (1.46, 14.94) | 0.001 |
| Quintile 1 | 1.88 (0.52, 6.82) | 0.337 |
| Quintile 2 | 2.21 (0.65, 7.57) | 0.206 |
| Quintile 3 | 4.84 (1.55, 15.13) | 0.007 |
| Quintile 5 | 4.67 (1.46, 14.94) | 0.001 |

Quintile 1: TG/HDL-c ratio <1.44. Quintile 2: 1.44≤ TG/HDL-c ratio <2.09. Quintile 3: 2.09≤ TG/HDL-c ratio <2.97. Quintile 4: 2.97≤ TG/HDL-c ratio <4.11. Quintile 5: TG/HDL-c ratio ≥4.11. MACCEs, major adverse cardiovascular and cerebrovascular events; HR, hazard ratio; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; inf, infinity; CKD, chronic kidney disease; TG/HDL-c, triglyceride to high-density lipoprotein cholesterol.

Table S5 Results for the tests of equality of group means to test for difference in the means across ARAEs groups once redundant variables have been removed

| Variables | Wilks' lambda | F | df1 | df2 | Sig. | Rank |
|----------------------|---------------|-------|-----|-----|-------|------|
| Hypertension | 0.986 | 8.34 | 1 | 935 | 0.004 | 1 |
| TyG index | 0.987 | 7.538 | 1 | 935 | 0.006 | 2 |
| Uric acid | 0.988 | 6.862 | 1 | 935 | 0.009 | 3 |
| WBC | 0.991 | 5.07 | 1 | 935 | 0.025 | 4 |
| Pericardial effusion | 0.993 | 4 | 1 | 935 | 0.046 | 5 |
| DBP | 0.995 | 2.795 | 1 | 935 | 0.095 | 6 |
| HDL-C | 0.996 | 2.343 | 1 | 935 | 0.126 | 7 |
| Diabetes mellitus | 0.997 | 1.976 | 1 | 935 | 0.16 | 8 |
| CAD | 0.997 | 1.807 | 1 | 935 | 0.179 | 9 |
| Pleura effusion | 0.997 | 1.707 | 1 | 935 | 0.192 | 10 |
| Male | 0.998 | 1.239 | 1 | 935 | 0.266 | 11 |
| Timing of operation | 0.999 | 0.52 | 1 | 935 | 0.471 | 12 |
| Platelet | 0.999 | 0.519 | 1 | 935 | 0.472 | 13 |
| COPD | 0.999 | 0.344 | 1 | 935 | 0.558 | 14 |
| BMI | 0.999 | 0.295 | 1 | 935 | 0.587 | 15 |
| Stroke | 1 | 0.181 | 1 | 935 | 0.671 | 16 |
| LDL-C | 1 | 0.123 | 1 | 935 | 0.726 | 17 |
| Smoking | 1 | 0.12 | 1 | 935 | 0.73 | 18 |
| CKD | 1 | 0.039 | 1 | 935 | 0.844 | 19 |
| Creatinine | 1 | 0.015 | 1 | 935 | 0.903 | 20 |
| SBP | 1 | 0.014 | 1 | 935 | 0.907 | 21 |
| Age | 1 | 0.004 | 1 | 935 | 0.952 | 22 |

ARAEs, aortic-related adverse events; df, degree of freedom; Sig., significance; TyG, triglyceride-glucose; WBC, white blood cell; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; CKD, chronic kidney disease; SBP, systolic blood pressure.

Table S6 Canonical discriminant analysis efficiency parameters to determine the significance of each canonical discriminant function

| Test of function | Wilks' lambda | Chi-square | df | Sig. |
|------------------|---------------|------------|----|-------|
| 1 through 8 | 0.963 | 21.915 | 1 | 0.000 |

df, degree of freedom; Sig., significance.